Imnovid

Indicated For

multiple myeloma

About This Medication

# Bristol-Myers Squibb Patient Assistance Foundation (BMSPAF) Patient Guide: How to Get Imnovid (pomalidomide) at Low or No Cost Imnovid (pomalidomide) is a prescription medication used to treat multiple myeloma in adults who have received at least two prior therapies, including lenalidomide and bortezomib. The **Bristol-Myers Squibb Patient Assistance Foundation (BMSPAF)** offers this drug **free of charge** to eligible uninsured or underinsured patients based on financial need. ## About Imnovid (pomalidomide) **Imnovid**, also known as pomalidomide, belongs to a class of drugs called immunomodulatory agents. It works by helping the immune system attack cancer cells and by stopping the growth of new blood vessels that tumors need to grow. Doctors typically prescribe it for relapsed or refractory multiple myeloma—a type of blood cancer affecting plasma cells—after other treatments like Revlimid (lenalidomide) and Velcade (bortezomib) have failed. Common side effects include low blood cell counts (leading to fatigue, infections, or bleeding), nerve issues, diarrhea, and constipation. Serious risks involve blood clots, birth defects (it's related to thalidomide, so strict pregnancy prevention is required), and second cancers. Always take it exactly as prescribed, usually with dexamethasone, and follow your doctor's monitoring schedule for blood tests. This guide focuses on accessing Imnovid through BMSPAF, not medical advice. Consult your healthcare provider for personalized information. ## Who Qualifies for BMSPAF? BMSPAF helps U.S. residents (including Puerto Rico) aged 18+ who lack prescription coverage or can't afford their medicine's costs. Key requirements: - **Uninsured or underinsured**: No coverage for the drug, or coverage exists but out-of-pocket costs are unaffordable. - **Needs-based**: Household income must meet guidelines (typically <400-500% Federal Poverty Level, though exact thresholds vary yearly and aren't fixed; program reviews case-by-case). - **U.S. residency**: Valid only for U.S. and Puerto Rico residents. - **Prescription needed**: From a licensed U.S. provider. Medicare Part D patients may qualify if they've spent at least **3% of annual household income** on out-of-pocket prescription costs that year, with proof. Meeting criteria doesn't guarantee approval—BMSPAF evaluates holistically. ## Income Eligibility Breakdown BMSPAF is **needs-based** without published fixed income thresholds for specific household sizes. Eligibility depends on total annual household income (wages, pensions, Social Security, child support, etc.) compared to Federal Poverty Guidelines (FPL), often up to 400-500% FPL, adjusted yearly. They may request proof like tax returns (1040), W-2s, 1099s, pay stubs, or SSA-1099s. Here's a general **2026 FPL reference table** (approximate; confirm current via HHS.gov as BMSPAF aligns closely): | Household Size | 100% FPL | 400% FPL | 500% FPL | |---------------|----------|----------|----------| | 1 (Individual) | $15,060 | $60,240 | $75,300 | | 2 (Couple) | $20,440 | $81,760 | $102,200| | 3 | $25,820 | $103,280| $129,100| | 4 | $31,200 | $124,800| $156,000| | +1 per add'l | +$5,380 | +$21,520| +$26,900| **Notes**: Add ~$5,380 per extra person. Medicare Part D adds the 3% spend rule. Provide most recent proof; non-filers use IRS Form 4506-T. ## Insurance Requirements - **Uninsured**: Ideal candidates—no private, Medicaid, Medicare Part D, VA, or state coverage for the drug. - **Underinsured**: Coverage exists, but high copays/deductibles make it unaffordable. Medicare Part D enrollees need proof of ≥3% income spent on Rx costs. - **Exclusions**: Active Medicaid often disqualifies; check specifics. BMSPAF verifies via your application and may contact insurers. ## Step-by-Step Application Process 1. **Discuss with your doctor**: Confirm Imnovid suitability. Ask them to complete provider sections. 2. **Get the form**: Download from bmspaf.org or call **800-736-0003** (Mon-Fri, 8am-8pm ET). [1][2][3] 3. **Complete patient section (Section I)**: Name, DOB, SSN (optional), address, household size/income, current meds, insurance status. Sign agreement/consent. [3] 4. **Gather documents**: - Proof of income (tax return, pay stubs, etc.). - Medicare Part D: Pharmacy printout of out-of-pocket spend. - List of meds. 5. **Doctor completes Sections II-III**: Treatment info, prescription (attach separate), provider details, shipping choice (office or home). Sign certification. [3][6] 6. **Submit**: - **Mail**: Bristol-Myers Squibb PAF, PO Box 1058, Somerville, NJ 08876 or PO Box 220769, Charlotte, NC 28222-0769. [3][5] - **Fax**: 800-736-1611. [3][5] - Phone support: 800-736-0003. [1][3] 7. **Track**: Note case # if provided. They'll notify by mail. **Tip**: Complete everything—missing info delays processing. ## Timeline and Delivery Processing takes **2-4 weeks** typically, but varies. If approved, receive **90-day supply** shipped free to doctor's office or home. Coverage lasts up to **12 months** (expires 12 months from approval; Medicare patients reapply Jan). [6][5] ## Reauthorization and Refills **Reauthorization required** annually (or sooner if status changes). Resubmit full application with updated income/insurance proof before supply ends. Notify BMSPAF of income/insurance changes immediately. [3][6] ## Alternatives if Denied - **Appeal**: Call 800-736-0003 for reasons and resubmit fixes. - **BMS Access Support**: Co-pay help for insured (bmsaccesssupport.com). [4][7] - **Other PAPs**: RxHope, NeedyMeds, or PAN Foundation for multiple myeloma. - **State programs**, generic options (none for pomalidomide), or clinical trials via ClinicalTrials.gov. - **Medicare Extra Help** if low-income. ## Disclaimer This guide is for informational purposes based on publicly available BMSPAF details as of 2026. Programs change; verify at bmspaf.org or by phone. Not medical/financial advice. Eligibility not guaranteed. Bristol Myers Squibb/BMSPAF can modify/terminate anytime. Consult professionals for your situation. Word count: 1028.

Program information last verified: March 29, 2026